Download Files:
Epalrestat
SKU
HY-66009-10 mg
Category Reference compound
Tags Aldose Reductase, Cancer; Metabolic Disease; Inflammation/Immunology, Metabolic Enzyme/Protease
$35 – $176
Products Details
Product Description
– Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy[1][2][3].
Web ID
– HY-66009
Storage Temperature
– -20°C (Powder, protect from light)
Shipping
– Blue Ice
Applications
– Metabolism-sugar/lipid metabolism
Molecular Formula
– C15H13NO3S2
References
– [1]He J, et al. The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation. Acta Pharmacol Sin. 2019 Jan;40(1):86-97.|[2]Sato K, et al. Epalrestat increases intracellular glutathione levels in Schwann cells through transcription regulation. Redox Biol. 2013 Nov 19;2:15-21.|[3]Li QR, et al. Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway. Neural Regen Res. 2016 Feb;11(2):345-51.|[4]Zhang T, et al. The Aldose Reductase Inhibitor Epalrestat Maintains Blood-Brain Barrier Integrity by Enhancing Endothelial Cell Function during Cerebral Ischemia. Mol Neurobiol. 2023 Jul;60(7):3741-3757.|[5]Ramirez, M.A. and N.L. Borja, Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy. Pharmacotherapy, 2008. 28(5): p. 646-55.|[6]Okamoto, H., et al., Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis. Intern Med, 2003. 42(8): p. 655-64.|[7]Hotta, N., et al., Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan. J Diabetes Complications, 1996. 10(3): p. 168-72.
CAS Number
– 82159-09-9
Molecular Weight
– 319.40
Compound Purity
– 99.72
SMILES
– O=C(O)CN(C/1=O)C(SC1=C/C(C)=C/C2=CC=CC=C2)=S
Clinical Information
– Launched
Research Area
– Cancer; Metabolic Disease; Inflammation/Immunology
Solubility
– DMSO : 20 mg/mL (ultrasonic)
Target
– Aldose Reductase
Pathway
– Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.